Saptaparni Ghosh, et al., The Oncologist
Currently, there are no guidelines for chemotherapy administration in hepatitis C virus-positive patients with breast cancer. This article addresses the knowledge gap, comparing breast cancer patients with and without concurrent hepatitis C virus to determine level of tolerance to treatment.
Discussions with Don S. DizonDon S. Dizon is the Director of Women's Cancers at Lifespan Cancer Institute, Founder of The Oncology Sexual Health First Responders Clinic at Lifespan Cancer Institute, and Director of Medical Oncology at Rhode Island Hospital. Dr. Dizon is a Professor of Medicine at the Warren Alpert Medical School of Brown University.
Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.
Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.
Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.
Subscribe to our videos featuring science advancing research below.
